Clinical Trial Update: A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing SEL-212 to KRYSTEXXA in patients with chronic gout refractory to conventional therapy has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• KRYSTEXXA (pegloticase)
• SEL-212

Snippet

Sponsor: Selecta Biosciences, Inc. | Conditions: Chronic Gout | Phase 2 | Status: COMPLETED | Results posted: 2023-10-17